Novo Nordisk pushes oral obesity drugs as shares stay under pressure

The wire

1. 01Yahoo Finance reports Novo Nordisk is advancing oral obesity candidates through its pipeline while its shares face steep pressure.
2. 02Oral incretins would reshape dispensing and adherence assumptions for pharmacies and telehealth programs built on injectables.
3. 03The report gives no trial data, dosing or timelines, so the clinical standing of the oral programs remains unclear.

From the source

Novo Nordisk Pipelines Oral Obesity Drugs As Shares Face Steep Pressure